NASDAQ:KOD Kodiak Sciences (KOD) Stock Price, News & Analysis $6.55 -0.01 (-0.15%) (As of 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Kodiak Sciences Stock (NASDAQ:KOD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kodiak Sciences alerts:Sign Up Key Stats Today's Range$6.43▼$6.9550-Day Range$2.51▼$6.5652-Week Range$2.18▼$7.77Volume390,041 shsAverage Volume475,592 shsMarket Capitalization$344.66 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingReduce Company OverviewKodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Read More… Massive shakeup in defense contracting (Ad)There is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.You need to check out the full story right here. Kodiak Sciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreKOD MarketRank™: Kodiak Sciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 466th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.8 / 5Analyst RatingReduce Consensus RatingKodiak Sciences has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 2 hold ratings, and 2 sell ratings.Amount of Analyst CoverageKodiak Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Kodiak Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kodiak Sciences are expected to decrease in the coming year, from ($3.48) to ($3.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kodiak Sciences is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kodiak Sciences is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKodiak Sciences has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.78% of the float of Kodiak Sciences has been sold short.Short Interest Ratio / Days to CoverKodiak Sciences has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Kodiak Sciences has recently increased by 3.85%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKodiak Sciences does not currently pay a dividend.Dividend GrowthKodiak Sciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.87 Percentage of Shares Shorted2.78% of the float of Kodiak Sciences has been sold short.Short Interest Ratio / Days to CoverKodiak Sciences has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Kodiak Sciences has recently increased by 3.85%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News Sentiment0.96 News SentimentKodiak Sciences has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kodiak Sciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for KOD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kodiak Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders45.30% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kodiak Sciences' insider trading history. Receive KOD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KOD Stock News HeadlinesKodiak Sciences' SWOT analysis: biotech firm's stock faces pivotal trialsNovember 23, 2024 | uk.investing.comKodiak Sciences (NASDAQ:KOD) Price Target Raised to $4.00November 18, 2024 | americanbankingnews.comJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.November 27, 2024 | Priority Gold (Ad)Kodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 17, 2024 | finanznachrichten.deKodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)November 15, 2024 | seekingalpha.comKodiak Sciences price target raised to $4 from $3 at BarclaysNovember 15, 2024 | markets.businessinsider.comKodiak Sciences Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comKodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 14, 2024 | prnewswire.comSee More Headlines KOD Stock Analysis - Frequently Asked Questions How have KOD shares performed this year? Kodiak Sciences' stock was trading at $3.04 on January 1st, 2024. Since then, KOD stock has increased by 115.5% and is now trading at $6.55. View the best growth stocks for 2024 here. How were Kodiak Sciences' earnings last quarter? Kodiak Sciences Inc. (NASDAQ:KOD) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by $0.14. When did Kodiak Sciences IPO? Kodiak Sciences (KOD) raised $126 million in an initial public offering on Thursday, October 4th 2018. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers. Who are Kodiak Sciences' major shareholders? Top institutional shareholders of Kodiak Sciences include State Street Corp (1.55%), Geode Capital Management LLC (1.46%), Jacobs Levy Equity Management Inc. (1.10%) and GSA Capital Partners LLP (0.55%). Insiders that own company stock include Bros Advisors Lp Baker, John A Borgeson, Jason Ehrlich and Victor Perlroth. View institutional ownership trends. How do I buy shares of Kodiak Sciences? Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kodiak Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kodiak Sciences investors own include NVIDIA (NVDA), Datadog (DDOG), CrowdStrike (CRWD), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Splunk (SPLK). Company Calendar Last Earnings11/09/2021Today11/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KOD CUSIPN/A CIK1468748 Webkodiak.com Phone(650) 281-0850FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$5.00 Low Stock Price Target$2.00 Potential Upside/Downside-46.6%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-260,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.52% Return on Assets-45.40% Debt Debt-to-Equity RatioN/A Current Ratio8.42 Quick Ratio8.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.52 per share Price / Book1.86Miscellaneous Outstanding Shares52,620,000Free Float28,785,000Market Cap$344.66 million OptionableOptionable Beta2.26 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:KOD) was last updated on 11/27/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kodiak Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.